Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
- O. Cornely, J. Maertens, D. Angulo-Gonzalez
- Medicine, BiologyNew England Journal of Medicine
- 25 January 2007
In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazoles prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival.
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research…
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
- O. Cornely, M. Bassetti, A. Ullmann
- Medicine, BiologyClinical Microbiology and Infection
- 1 December 2012
This part of the EFISG guidelines focuses on non-neutropenic adult patients, and liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength for the targeted initial treatment of candidaemia.
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Caspofungin is as effective as and generally better tolerated than liposomal amphotericin B when given as empirical antifungal therapy in patients with persistent fever and neutropenia.
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.
COVID‐19 associated pulmonary aspergillosis
This study evaluates coronavirus disease 19 (COVID‐19) associated invasive aspergillosis at a single centre in Cologne, Germany to evaluate patients with acute respiratory distress syndrome due to viral infection.
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update
The goal of this paper is to summarize the new proposals from ECIL 3, based on the results of studies published after the ECIL 2 meeting, and the prophylactic recommendations for hematopoietic stem cell transplant recipients were formulated differently.